OSI Buys Eyetech, Market Rubs Eyes

Not the most obvious of biotech-biotech combinations. OSI thinks it can make money from Eyetech's lone product pegaptanib (Macugen), a breakthrough new treatment for age-related macular degeneration. The market has reacted poorly to the deal, worried that Macugen will be made obsolete by Genentech's Lucentis, due to be launched in late 2006.

Some biopharma transactions, once announced, are relatively obvious. Observers had been pointing out the likelihood of GlaxoSmithKline PLC buying ID Biomedical Corp. for some time before GSK bought the smaller flu vaccine producer for $1.4 billion in early September, for example. [See Deal] But few can claim to have called OSI Pharmaceuticals Inc. 's surprise acquisition of Eyetech Pharmaceuticals Inc. for $935 million in cash (75%) and stock just two weeks earlier. [See Deal] And given the market's reaction to the deal—at press time OSI's stock was down nearly 20%, bringing the deal value below $900 million—even fewer were thrilled with the combined company's prospects.

At first glance it's hard to see where OSI thinks it can make money from Eyetech's lone product pegaptanib (Macugen),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By 

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.